For U.S. Healthcare Professionals Only

For Healthcare Professionals


The Microsponge®

The unique difference of the Microsponge®


Carac® is the only topical fluorouracil that:
  • Delivers fluorouracil through a patented Microsponge® system
  • Offers once-a-day dosing
    • QD dosing may offer a compliance advantage4

The Microsponge® concentrates treatment where it's needed

  • 89% of fluorouracil is retained in the skin5†‡
  • Targeted Microsponge® technology delivers a consistent, sustained release of fluorouracil3,6-8‡

Microsponge®-based 0.5% fluorouracil cream

89% fluorouracil is retained in the skin

* For the topical treatment of AK lesions.
† In vitro study investigating the flux and percutaneous absorption of fluorouracil through cadaver skin.
‡ Clinical significance of these findings is unknown.

Microsponge® is a registered trademark of Cardinal Health, Inc., its successors and assigns.

[Image of grass][Image of grass]
Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
IMPORTANT SAFETY INFORMATION
Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.
For more information, please see Full Prescribing Information for Carac®.